Hemispherx BioPharma, Inc. (AMEX:HEB)
A biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug entities based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
mrcarlen
(< 20)
Submitted: 11/17/2010 7:44:41 PM :
Start Price:
$0.51
HEB Score:
+43.80
Projections don't look good
Recs
zzlangerhans
(99.23)
Submitted: 8/25/2010 4:32:51 AM :
Start Price:
$0.49
HEB Score:
-56.24
Hemispheryx puts me in mind of a novel called Perfume, by Patrick Susskind. The protagonist is a murderer who lies dormant for years, likened to a tick on a branch, simply awaiting the passage of a warm-blooded animal to latch on and begin sucking its blood.
Hemispheryx the tick left its last host in December, when the FDA finally rejected the Ampligen NDA, and has laid dormant throughout 2010. I believe that soon the tick will sense another blood meal. If not at 0.5, then at 0.4 or maybe 0.3. Don't let your blood get sucked by this tick ...
Recs
Displacement
(32.21)
Submitted: 9/28/2009 3:20:59 PM :
Start Price:
$2.05
HEB Score:
-110.10
Will this be big in a year? Nahh. Will this be big in a couple months when the FDA pushes through the H1N1 kit? Sure. Riding it short term because there's decent support at 2 and it might get another launch before it sputters out.
Recs
Recs
AbeNebo
(< 20)
Submitted: 9/1/2009 12:21:23 AM :
Start Price:
$2.37
HEB Score:
-118.46
If FDA Approve.
Recs
redwings103149
(62.09)
Submitted: 8/24/2009 6:09:10 PM :
Start Price:
$2.14
HEB Score:
-114.82
Under heavy accumulation by barclays and other major players who know alot more than we do. Time to jump on baby
Recs
BustaCAPS
(36.61)
Submitted: 8/14/2009 10:56:37 AM :
Start Price:
$1.97
HEB Score:
+117.95
UltraLong play
Recs
Brian7992
(< 20)
Submitted: 8/11/2009 2:29:09 PM :
Start Price:
$1.99
HEB Score:
-118.26
Love this one
Recs
Slam54
(< 20)
Submitted: 7/10/2009 1:21:22 AM :
Start Price:
$2.22
HEB Score:
-139.06
Pending FDA approval
Recs
Siforus
(< 20)
Submitted: 6/25/2009 8:27:28 PM :
Start Price:
$2.36
HEB Score:
-133.17
Ampligen will be approved.
The Swiss have their hands all in this stuff!
Recs
scrxdagain
(< 20)
Submitted: 6/24/2009 3:57:51 PM :
Start Price:
$1.89
HEB Score:
-132.90
Despite a dubious history for Ampligen, and some sloppy business moves, the drug will be approved. Once that happens, the likelihood of approval for a second orphan drug increases dramatically.
Recs
marginaddict
(< 20)
Submitted: 6/22/2009 10:51:28 PM :
Start Price:
$2.13
HEB Score:
+135.34
Snake oil.
Recs
prcltrader
(58.06)
Submitted: 6/19/2009 11:39:49 AM :
Start Price:
$2.46
HEB Score:
-133.49
Waiting on FDA approval for Ampligen.
Recs
kropopkin
(21.72)
Submitted: 6/11/2009 7:16:39 AM :
Start Price:
$2.52
HEB Score:
+130.52
There is so much pumping on little hard evidence, and a lot of smoke and mirrors being used here. Also, a large boost to the price based on the swine flu adjuvant aspect, where as it seems lost on the masses that possible FDA approval is for CFS and not a vaccination adjuvant.
Possible that it all comes together, but I wouldn't be putting my money into this murky waters at the moment.
Recs
jjupita
(< 20)
Submitted: 6/5/2009 5:15:13 PM :
Start Price:
$2.99
HEB Score:
-133.87
Normally when investing in a company, I consider recommendations, then I evaluate fundamentals, and finally I make an emotional decision.
I admit that HEB is not backed by fundamentals, so I'm breaking my own rule. It's trading on hype (read: fun), and is therefore purely speculative. That's why I've only got disposable cash behind it right now.
But consider the following - there are no FDA approved drugs on the market for Chronic Fatigue Syndrome. It will need to be treated somehow, someway. Anybody else working on a solution?
Perhaps more buzzworthy is all the H1N1/H5N1 discussion. Everyone is racing for a cure. Japan - where normal people where face masks in public - thinks HEB is most likely to have it.
Consider lastly the decidedly negative articles written time and time again by Adam Feuerstein. I can't help but question his journalistic ethics - someone, if not him, stands to gain whenever his missives shrink the stock. He claims that HEB's CEO is maniuplating the news to benefit the stock price. There's a novel idea, a CEO who wants his stock price to GO UP! Of course he does - that's what CEO's of company DO! So I have to wonder, why does Feuerstein want the stock to go down? I'm hoping it's so he can buy shares cheaper!!! Guess we can all thank him for the temporary discount.
All in, I think the upside is worth the risk. No Ampligen FDA approval and no deals with Japan means $2.50/share going back to $.25 pretty quickly - sucks, I admit. But $2.50 going to $10 is a vacation to someplace tropical.
See you on the beach!
Recs
dudefucker
(< 20)
Submitted: 6/4/2009 11:03:35 PM :
Start Price:
$4.09
HEB Score:
+134.51
This stock is overpriced. Even if FDA approves, how far do you think this stock price would climb?
Recs
giggy63
(< 20)
Submitted: 5/30/2009 12:20:22 PM :
Start Price:
$1.75
HEB Score:
-125.73
Ampligen will be approved.
Recs
Recs
LayZJester
(< 20)
Submitted: 5/21/2009 1:41:12 AM :
Start Price:
$1.80
HEB Score:
-133.16
Long term perspective is a green light for me. With cash infusion, this company will last for a while even if FDA does not approve.
Recs
artisan99
(< 20)
Submitted: 10/26/2007 12:36:07 AM :
Start Price:
$1.85
HEB Score:
-73.46
If the data shows that Ampligen help CFS then this could be the story that pushes HEB much higher. However, one stock that is too small to put on this site is Nanoviricides NNVC and it will far outperform HEB in the 2 - 4 year time frame for anti-virus vaccines especially bird flu, Hep C, Rabies and even HIV
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 35 : 1 2 Next »